CN100394983C - Doramectin injection fluid containing soyban oil - Google Patents
Doramectin injection fluid containing soyban oil Download PDFInfo
- Publication number
- CN100394983C CN100394983C CNB2006100001955A CN200610000195A CN100394983C CN 100394983 C CN100394983 C CN 100394983C CN B2006100001955 A CNB2006100001955 A CN B2006100001955A CN 200610000195 A CN200610000195 A CN 200610000195A CN 100394983 C CN100394983 C CN 100394983C
- Authority
- CN
- China
- Prior art keywords
- injection
- doractin
- soybean oil
- ethyl oleate
- phenol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a doramectin injection for treating parasitic diseases and a preparation method thereof. The doramectin injection of the present invention is prepared from doramectin, ethyl oleate, phenol, BHA and soybean oil for injection; the doramectin injection prepared by the present invention has the advantages of rapid absorption, lasting drug effect, rich auxiliary material sources and optimal stability.
Description
Technical field
The present invention relates to a kind of veterinary formulations for the treatment of parasitic disease, particularly, the present invention relates to that a kind of what treat parasitic disease is doractin injection of solvent and preparation method thereof with the soybean oil.
Background technology
Doractin (Doramectin, the CAS accession number is 117704-25-3) is the Avermectins anti-parasite medicine for animal use, and chemical name is that 25-cyclohexyl-5-O-demethyl-25-removes (1-methyl-propyl) avilamycin A
1a, structural formula is as follows:
This chemical compound is a kind of of Avermectins, and U.S. Pat 5089480A has protected this chemical compound, and illustrates that this chemical compound is highly active antiparasitic, can be used as anthelmintic, kills epizoa agent, insecticide and acaricide.
Antiparasitic is the parenterai administration preparation for animal administered formulation the most commonly used.Usually, water is a kind of convenient injection liquid that uses, and still, the dissolubility of Avermectins in water is too low, and its simple concentration of aqueous solution is very low, can't use.Use surfactant to form micelle solution, some avilamycin is dissolved in water as chaotropic agent and the suitable organic cosolvent of use.But the dosage of the chemical compound that these preparations provided can not be removed the inside and outside parasite of animal body satisfactorily.
EP146414A discloses the cosolvent solution of Avermectins, and the glyceroformol that contains low amounts of water and the mixed liquor or the propylene glycol of propylene glycol are wherein arranged, and uses for parenterai administration.But known propylene glycol causes stimulation in subcutaneous or intramuscular injection meeting; And low amounts of water wherein can cause the active component hydrolysis.
Disclose among the GB2166436A and used Oleum Arachidis hypogaeae semen, Oleum Gossypii semen and ethyl oleate solvent as some Avermectins, but, the solution that Oleum Arachidis hypogaeae semen and Oleum Gossypii semen provide can not make the concentration of doractin reach 1%w/v at least, and this general just veterinary drug is desired.
The inventor is through conscientiously discovering for many years, and use soybean oil and ethyl oleate mix according to a certain percentage and handle, and can obtain qualified doractin injection, has therefore finished the present invention.
Summary of the invention
The purpose of this invention is to provide a kind of doractin injection for the treatment of parasitic disease;
Another object of the present invention has provided a kind of method for preparing the doractin injection.
The objective of the invention is to realize by following technical proposal:
The inventor discovers that soybean oil is widely used in intramuscular injection as drug solvent, and clinical use for many years, by " Chinese pharmacopoeia is recorded, and quality standard is comparatively perfect, and safety is good, chemical property is also more stable, is considered to totally nontoxic, non-irritating material.Therefore, we select for use ethyl oleate and soybean oil (injection) as the solvent of injection of the present invention, prepare doractin injection of the present invention.
Research finds that also doractin belongs to Avermectins, and such material such as avilamycin, ivermectin etc. are exposed to easily oxidative degradation in the air owing to contain a plurality of ethylene linkages in the structure.Therefore, the inventor adds tertiary butyl-4-hydroxy methoxybenzene (BHA) as the oiliness antioxidant in injection of the present invention, prevent doractin oxidative degradation.And the present invention uses phenol as antiseptic.
Through test, when the part by weight of soybean oil/ethyl oleate is 9: 1, be heated to 80 ℃ and can guarantee that sample dissolves fully, and the made preparation of this ratio has passed through the investigation of pharmacodynamics test, therefore, preferred operating weight ratio is 9: 1 a soybean oil: the ethyl oleate solvent is as the injection solvent.
Therefore, the invention provides a kind of doractin injection of mainly forming by doractin, ethyl oleate and soybean oil; Injection of the present invention can also add antiseptic and antioxidant, and wherein antiseptic is selected from phenol, benzyl alcohol, preferred phenol; Antioxidant is selected from tertiary butyl-4-hydroxy methoxybenzene (BHA), 2,6 ditertiary butyl p cresol (BHT), preferred BHA.
Particularly, (percetage by weight) preferably composed as follows of doractin injection of the present invention:
Doractin 0.1-3%
Ethyl oleate 5%-50%
Phenol 1-10%
Tertiary butyl-4-hydroxy methoxybenzene (BHA) 0.005-0.5%
Surplus is the injection soybean oil
Doractin injection of the present invention can prepare by following method:
Prescription:
Doractin 10mg
Ethyl oleate 0.1ml
Phenol 2.5mg
BHA 0.2mg
The injection soybean oil adds to 1.00ml
Method for making:
The ethyl oleate of recipe quantity is mixed with the injection soybean oil, and be heated to 60 ℃～100 ℃, preferred 80 ℃, purge with nitrogen simultaneously, add doractin (content＞95% is provided by Haizheng Medicine Stock Co., Ltd., Zhejiang Prov's production) and BHA, stir and make dissolving, be cooled to room temperature rapidly, add phenol, stir, add the injection soybean oil to 1ml, stir, with the membrane filtration degerming of 0.22 μ m, 100 grades of aseptic area fills in exsiccant molded antibiotic glass bottle, cover sterilizing-drying plug, aluminium lid, roll the cap seal mouth, packing is handed over the storehouse after the assay was approved.
That doractin injection that the present invention prepares absorbs is fast, lasting medicine, adjuvant convenient sources, have preferable advantages such as stability.
The specific embodiment
Further specify the present invention below by embodiment.It should be understood that embodiments of the invention are to be used to illustrate the present invention rather than limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Except as otherwise noted, the percent among the present invention is meant percetage by weight.
Embodiment 1: preparation doractin injection
Prepare injection with following compositions, ethyl oleate is mixed with the injection soybean oil, and be heated to 80 ℃, purge with nitrogen simultaneously, add doractin and BHA, stir and make dissolving, be cooled to room temperature rapidly, add phenol, stir, add the injection soybean oil to 1ml, stir, with the membrane filtration degerming of 0.22 μ m, 100 grades of aseptic area fills are in exsiccant molded antibiotic glass bottle, cover sterilizing-drying plug, aluminium lid, roll the cap seal mouth, the packing, hand over the storehouse after the assay was approved.
Doractin 10mg
Ethyl oleate 0.1ml
Phenol 2.5mg
Tertiary butyl-4-hydroxy methoxybenzene 0.2mg
The injection soybean oil adds to 1.00ml
Embodiment 2: preparation doractin injection
Adopt and implement 1 preparation method, only change the doractin recipe quantity into 1mg, prepare qualified doractin injection.
Embodiment 3: preparation doractin injection
Adopt and implement 1 preparation method, only change the doractin recipe quantity into 20mg, prepare qualified doractin injection.
Embodiment 4: preparation doractin injection
Adopt and implement 1 preparation method, only change the ethyl oleate recipe quantity into 0.5ml, prepare qualified doractin injection.
Embodiment 5: preparation doractin injection
Adopt and implement 1 preparation method, only heating-up temperature is changed into 100 ℃, prepare qualified doractin injection.
For verifying the feasibility study of this technology.Doractin injection by the foregoing description 1 prepared has been carried out stability test, and this injection and import contrast medicine is " logical
" injection (
, Pfizer Inc. produces) pharmacokinetics bioequivalence and target animals irritation test, the result is as follows:
1, stability test
Get according to doractin injection 030601,030602,030,603 3 batch samples of embodiment 1 prepared an amount of, simulation listing packing instructions, put 25 ± 2 ℃, in relative humidity RH60 ± 5% climatic chamber, respectively at 0,6,12,18,24 month sample analysis, detect by " import veterinary drug quality standard " (revised edition in 2003), and compare, the results are shown in Table with 0 day result.
Doractin injection long-term test results
Conclusion: this product long term test after 24 months content slightly descend, related substance increases 1-2%, every investigation index has no significant change, quality is comparatively stable.Prompting show add antioxidant BHA in this product prescription after, stability is significantly improved, it is 2 years that effect duration can fix tentatively.
2, pharmacokinetics bioequivalence test
The injection and the imported medicine of entrusting China Agricultural University to carry out the embodiment of the invention 1 preparation " are led to
Injection " pharmacokinetics bioequivalence test, the result is as follows:
Pig intramuscular injection 300 μ g/kg body weight doractin pharmacokinetics parameters (n=6)
t
1/2: eliminate the half-life; T: peak time; H: the time (hour); C: blood peak concentration of drug; AUC: medicine is area under curve for the moment; MRT: average residence time
Result of the test shows that the pharmacokinetics process is an one compartment open model in the pig intramuscular injection doractin injecting fluid, and is " logical with matched group
Injection " relatively, the doractin injection that my company produces absorbs, eliminates all slightly faster than in matched group, but the t assay shows parameters difference not significantly (p＞0.05), the two bioequivalence.
3, target animals irritation test
Entrust China Agricultural University to carry out the injection target animals tolerance test of the embodiment of the invention 1 preparation, the result shows that this prescription zest is few, and the animal toleration is good.
Claims (9)
1. a doractin injection for the treatment of parasitic disease is characterized in that with the soybean oil being solvent, mainly is made up of doractin, ethyl oleate and soybean oil.
2. according to the doractin injection of claim 1, it is made up of doractin, ethyl oleate, antiseptic, antioxidant and soybean oil.
3. according to the doractin injection of claim 2, wherein antiseptic is a phenol.
4. according to the doractin injection of claim 3, wherein antioxidant is the tertiary butyl-4-hydroxy methoxybenzene.
5. according to the doractin injection of claim 4, its percentage by weight is composed as follows:
Doractin 1-3%
Ethyl oleate 5%-50%
Phenol 1-10%
Tertiary butyl-4-hydroxy methoxybenzene 0.005-0.5%
Surplus is the injection soybean oil.
6. according to the injection of claim 5, soybean oil wherein: the part by weight of ethyl oleate is 9: 1.
7. according to the doractin injection of claim 5, it is composed as follows:
Doractin 10mg
Ethyl oleate 0.1ml
Phenol 2.5mg
Tertiary butyl-4-hydroxy methoxybenzene 0.2mg
The injection soybean oil adds to 1.00ml.
8. according to the preparation method of the doractin injection of one of claim 1-7, this method comprises mixes ethyl oleate with the injection soybean oil, be heated to 60-100 ℃, purge with nitrogen simultaneously, add doractin and tertiary butyl-4-hydroxy methoxybenzene, stir and make dissolving, be cooled to room temperature rapidly, add phenol, stir, add the injection soybean oil.
9. preparation method according to Claim 8 wherein is heated to 80 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100001955A CN100394983C (en) | 2006-01-09 | 2006-01-09 | Doramectin injection fluid containing soyban oil |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100001955A CN100394983C (en) | 2006-01-09 | 2006-01-09 | Doramectin injection fluid containing soyban oil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1824323A CN1824323A (en) | 2006-08-30 |
| CN100394983C true CN100394983C (en) | 2008-06-18 |
Family
ID=36935265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100001955A Active CN100394983C (en) | 2006-01-09 | 2006-01-09 | Doramectin injection fluid containing soyban oil |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100394983C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417477B (en) * | 2012-05-18 | 2015-08-05 | 中国农业科学院兰州畜牧与兽药研究所 | A kind of take water as doractin O/W type injection of substrate and preparation method thereof |
| CN103006559A (en) * | 2012-12-14 | 2013-04-03 | 江苏恒丰强生物技术有限公司 | Doramectin injection and preparation method thereof |
| CN107349236B (en) * | 2017-07-24 | 2020-10-23 | 佛山市南海东方澳龙制药有限公司 | Doramectin preparation and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2166436A (en) * | 1984-09-14 | 1986-05-08 | Glaxo Group Ltd | Antibiotic compounds and their preparation |
| CN1304727A (en) * | 2000-10-20 | 2001-07-25 | 王玉万 | Injection containing evericin or ivermectin and using benzyl benzoate or nitrone as co-solvent |
-
2006
- 2006-01-09 CN CNB2006100001955A patent/CN100394983C/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2166436A (en) * | 1984-09-14 | 1986-05-08 | Glaxo Group Ltd | Antibiotic compounds and their preparation |
| CN1304727A (en) * | 2000-10-20 | 2001-07-25 | 王玉万 | Injection containing evericin or ivermectin and using benzyl benzoate or nitrone as co-solvent |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1824323A (en) | 2006-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106474120B (en) | Parasiticidal compositions comprising isoxazoline active agents, methods and uses thereof | |
| RU2602189C2 (en) | Topical localized isoxazoline formulation comprising glycofurol | |
| JP5513403B2 (en) | Solvent system for pour-on formulations for controlling parasites | |
| EP2892347B1 (en) | Spirocyclic isoxazoline parasiticidal combinations | |
| US20030236203A1 (en) | Anthelmintic oral homogeneous veterinary pastes | |
| BRPI0615355B1 (en) | long-acting injectable formulations | |
| HU230959B1 (en) | Parasiticidal oral veterinary compositions comprising systematically-acting active agents, methods and uses thereof | |
| US20040019062A1 (en) | Parasiticidal formulation for animals | |
| EP0137627B1 (en) | Pour-on formulation for the control of parasites | |
| KR0169559B1 (en) | Pour-on formulations containing polymeric material, glycols and glycerides | |
| CN1684664A (en) | Injectable growth promoting and anthelmintic composition | |
| JP7558197B2 (en) | Injectable pharmaceutical compositions and uses thereof | |
| CN100394983C (en) | Doramectin injection fluid containing soyban oil | |
| CN103417478B (en) | Water based ivermectin O/W injection and preparation method thereof | |
| CN103006559A (en) | Doramectin injection and preparation method thereof | |
| AU2011268899C1 (en) | Injectable formulation of a macrocyclic lactone and levamisole | |
| AU2006100661A4 (en) | Topical formulation | |
| CN114588108A (en) | Oil-soluble solution containing insect-resistant agent and preparation method and application thereof | |
| CN1867341B (en) | Compositions for controlling parasites comprising a combination of abamectin and milbemycin | |
| CN107157995A (en) | A kind of compound imidacloprid transdermal composition preparation of pet broad-spectrum anti-parasite | |
| CN110721152B (en) | Sustained-release composition for treating animal skin parasite and fungus infection | |
| CN115671040B (en) | External preparation for controlling animal parasite infection | |
| RU2140737C1 (en) | Agent for prophylaxis and treatment of animals with parasitic sicknesses | |
| AU2013201479B2 (en) | Long Acting Compositions | |
| CN103417477A (en) | Doramectin O/W type injection taking water as matrix and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HISUN PHARMACEUTICAL (HANGZHOU) CO., LTD. Free format text: FORMER OWNER: HAIZHENG MEDICINE CO., LTD., ZHEJIANG PROV. Effective date: 20141020 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 318000 TAIZHOU, ZHEJIANG PROVINCE TO: 311400 HANGZHOU, ZHEJIANG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141020 Address after: 311400, Zhejiang City, Hangzhou province Fuyang Xu Town Village under practice Patentee after: Zhejiang Hisun Pharmaceutical Co., Ltd. Address before: Jiaojiang District of Taizhou City, Zhejiang province 318000 road outside No. 46 Patentee before: Zhejiang Hisun Pharmaceutical Co., Ltd. |